miR-141-3p在化疗耐药与敏感上皮性卵巢癌组织中的表达分析及其靶基因预测和验证

发布时间：2018-03-23 22:31

本文选题：miR-141-3p　切入点：靶基因　出处：《山西医科大学》2017年硕士论文

【摘要】：目的:检测miR-141-3p在两组上皮性卵巢癌(化疗耐药和敏感组)组织中的表达水平,探讨miR-141-3p在卵巢癌发生、发展中的作用以参与卵巢上皮性癌化疗耐药形成的分子机制。方法:应用3种生物信息学软件预测miR-141-3p的靶基因是TGF-β2,再用RT-PCR技术分别测定卵巢癌化疗耐药和敏感组中靶基因和mi R-141-3p的表达水平。结果:miR-141-3p在化疗耐药的卵巢癌组织和化疗敏感组中的△ct分别为7.13±2.64和8.87±2.23,P0.05,差异具有统计学意义。TGF-β2在化疗耐药的卵巢癌组织和化疗敏感组中的△ct分别为12.50±2.57和7.89±1.23,P0.05,差异具有统计学意义。结论:上皮性卵巢癌化疗耐药组中miR-141-3p的表达显著高于化疗敏感组;TGF-β2是miR-141-3p的靶基因。
[Abstract]:Objective: to detect the expression of miR-141-3p in two groups of epithelial ovarian carcinoma (chemotherapy-resistant and sensitive group) and to explore the occurrence of miR-141-3p in ovarian carcinoma. Methods: using three kinds of bioinformatics software to predict the target gene of miR-141-3p is TGF- 尾 2, and then determine the chemoresistance and sensitive group of ovarian cancer by RT-PCR technique. Results the expression levels of middle target gene and miR-141-3p were 7.13 卤2.64 and 8.87 卤2.23P0.05 in chemotherapy-resistant ovarian cancer and chemotherapy-sensitive group, respectively. The difference was statistically significant. TGF- 尾 2 was found in chemotherapeutic ovarian cancer and chemotherapeutic sensitive group. Conclusion: the expression of miR-141-3p in chemotherapeutic resistance group of epithelial ovarian cancer is significantly higher than that in chemotherapy-sensitive group. TGF- 尾 2 is the target gene of miR-141-3p.
【学位授予单位】：山西医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R737.31

【参考文献】